Articles from Regenerex Pharma, Inc.

Regenerex Pharma, Inc. (OTC: RGPX), a leading innovator in advanced wound closure systems for chronic wounds, today announced the development of new product formulations designed to accelerate deep tissue regeneration through enhanced scaffolding facilitation and cell proliferation. Building on its patented QBx™ technology, Regenerex will now incorporate ovine nano-collagen into its wound healing protocols. This highly refined biomaterial, due to its ultra-small molecular size, provides an ideal scaffolding matrix to support and accelerate cellular growth, making it especially beneficial in cases requiring deeper tissue regeneration.

Regenerex Pharma, Inc. (OTC: RGPX), announces the establishment of its comprehensive management team and the commencement of the Company manufacturing plans in Q4 2023. Regenerex Pharma’s products heal wounds effectively with its proprietary innovative formulas in the shortest period of time to minimize the chances of future complications. The products have shown to be very effective in healing chronic wounds in multiple clinical evaluations with 95% of wounds demonstrating 100% closure within 90 days. All of our products feature our proprietary QBx™ ingredients which contribute to setting up a suitable environment to allow wounds to close.